We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Acadia Healthcare Jumps 100% YTD on Improving Outlook and Expansion
Read MoreHide Full Article
Key Takeaways
Acadia Healthcare shares surged 100% YTD as its outlook improved after a sharp 2025 slump.
ACHC raised 2026 EBITDA, earnings and operating cash flow guidance while cutting expected capex.
Acadia Healthcare added 240 licensed beds through two new joint-venture facilities in Q2 2026.
Shares of Acadia Healthcare Company, Inc. (ACHC - Free Report) have surged 100% year to date, marking a sharp rebound from their 2025 slump. Investor sentiment had been weighed down by rising patient-related litigation costs and broader legal and liability concerns, which pressured the stock’s valuation. The industry rose 11.1% so far this year while the S&P 500 gained 13.2%.
YTD Price Performance – ACHC, Industry and S&P 500
Image Source: Zacks Investment Research
Early this year, Acadia brought back former CEO Debra Osteen, replacing Chris Hunter, while reaffirming its 2025 guidance. Investors appeared to welcome Osteen’s return as a potential source of greater operational discipline and stability.
Improving expectations also supported the rally. Management raised its 2026 adjusted EBITDA and earnings outlook following both first- and second-quarter results. After the second quarter, Acadia also increased its operating cash flow guidance to $350-$400 million from $285-$325 million and lowered its expected capital expenditures to $235-$255 million from $255-$280 million. The combination of stronger expected cash generation and lower spending provided additional support, particularly given Acadia’s elevated leverage.
Capacity expansion has also strengthened Acadia’s longer-term growth narrative. The company added 240 licensed beds in the second quarter of 2026 through two newly opened joint-venture facilities, a 144-bed facility with Orlando Health in Florida and a 96-bed facility with Methodist Jennie Edmundson Hospital in Iowa. Acadia also opened two new Comprehensive Treatment Center locations during the quarter.
Improving Estimates for ACHC
The Zacks Consensus Estimate for ACHC’s 2026 earnings is currently pegged at $1.55 per share, which witnessed four upward revisions and no cuts over the past 60 days. The consensus mark for 2027 EPS indicates a further 14.4% year-over-year growth. It beat earnings estimates in each of the past four quarters with an average surprise of 47%.
Meanwhile, the Zacks Consensus Estimate for ACHC’s 2026 and 2027 revenues is pegged at $3.42 billion and $3.61 billion, signaling 3.4% and 5.4% increases, respectively.
Zacks Rank & Key Picks
Acadia Healthcare currently has a Zacks Rank #3 (Hold).
The Zacks Consensus Estimate for Tenet Healthcare’s 2026 bottom line suggests 25.4% year-over-year growth. THC has witnessed nine upward estimate revisions over the past 60 days against no movement in the opposite direction. It beat earnings estimates in all the last four quarters, with an average surprise of 22.7%.
The Zacks Consensus Estimate for UnitedHealth’s full-year 2026 earnings indicates a 21.4% year-over-year increase. UNH beat earnings estimates in each of the past four quarters, with an average surprise of 12.1%. The consensus mark for 2026 revenues is pegged at $446.78 billion.
The Zacks Consensus Estimate for Ensign Group’s 2026 full-year earnings implies an 18.6% jump from the year-ago reported figure. ENSG beat earnings estimates in each of the last four quarters, with an average surprise of 4.3%. The consensus mark for its current-year revenues is pegged at $5.88 billion, which indicates a 16.3% year-over-year increase.
View the Zacks #1 Rank List
Image: Bigstock
Acadia Healthcare Jumps 100% YTD on Improving Outlook and Expansion
Key Takeaways
Shares of Acadia Healthcare Company, Inc. (ACHC - Free Report) have surged 100% year to date, marking a sharp rebound from their 2025 slump. Investor sentiment had been weighed down by rising patient-related litigation costs and broader legal and liability concerns, which pressured the stock’s valuation. The industry rose 11.1% so far this year while the S&P 500 gained 13.2%.
YTD Price Performance – ACHC, Industry and S&P 500
Early this year, Acadia brought back former CEO Debra Osteen, replacing Chris Hunter, while reaffirming its 2025 guidance. Investors appeared to welcome Osteen’s return as a potential source of greater operational discipline and stability.
Improving expectations also supported the rally. Management raised its 2026 adjusted EBITDA and earnings outlook following both first- and second-quarter results. After the second quarter, Acadia also increased its operating cash flow guidance to $350-$400 million from $285-$325 million and lowered its expected capital expenditures to $235-$255 million from $255-$280 million. The combination of stronger expected cash generation and lower spending provided additional support, particularly given Acadia’s elevated leverage.
Capacity expansion has also strengthened Acadia’s longer-term growth narrative. The company added 240 licensed beds in the second quarter of 2026 through two newly opened joint-venture facilities, a 144-bed facility with Orlando Health in Florida and a 96-bed facility with Methodist Jennie Edmundson Hospital in Iowa. Acadia also opened two new Comprehensive Treatment Center locations during the quarter.
Improving Estimates for ACHC
The Zacks Consensus Estimate for ACHC’s 2026 earnings is currently pegged at $1.55 per share, which witnessed four upward revisions and no cuts over the past 60 days. The consensus mark for 2027 EPS indicates a further 14.4% year-over-year growth. It beat earnings estimates in each of the past four quarters with an average surprise of 47%.
Meanwhile, the Zacks Consensus Estimate for ACHC’s 2026 and 2027 revenues is pegged at $3.42 billion and $3.61 billion, signaling 3.4% and 5.4% increases, respectively.
Zacks Rank & Key Picks
Acadia Healthcare currently has a Zacks Rank #3 (Hold).
Enhancing the array of healthcare options, promising stocks in the Medical sector include Tenet Healthcare Corporation (THC - Free Report) , UnitedHealth Group Incorporated (UNH - Free Report) and The Ensign Group, Inc. (ENSG - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Tenet Healthcare’s 2026 bottom line suggests 25.4% year-over-year growth. THC has witnessed nine upward estimate revisions over the past 60 days against no movement in the opposite direction. It beat earnings estimates in all the last four quarters, with an average surprise of 22.7%.
The Zacks Consensus Estimate for UnitedHealth’s full-year 2026 earnings indicates a 21.4% year-over-year increase. UNH beat earnings estimates in each of the past four quarters, with an average surprise of 12.1%. The consensus mark for 2026 revenues is pegged at $446.78 billion.
The Zacks Consensus Estimate for Ensign Group’s 2026 full-year earnings implies an 18.6% jump from the year-ago reported figure. ENSG beat earnings estimates in each of the last four quarters, with an average surprise of 4.3%. The consensus mark for its current-year revenues is pegged at $5.88 billion, which indicates a 16.3% year-over-year increase.